The Effectiveness of Ritonavir Plus Zidovudine Plus Lamivudine in HIV-Infected Patients
Status:
Completed
Trial end date:
2007-07-01
Target enrollment:
Participant gender:
Summary
To determine whether administration of a highly active antiretroviral treatment regimen
consisting of ritonavir (ABT-538), zidovudine (AZT), and lamivudine (3TC) is associated with
the restoration of delayed type hypersensitivity and lymphocyte proliferative responses in
patients with moderately advanced HIV-1 infection. To better characterize in these patients
the phenotype of the expanded lymphocyte subpopulations, as well as the genotype, phenotype,
and cellular origin of viruses that persist after initiation of therapy, and the genotype and
phenotype of drug-resistant isolates that emerge during therapy.
Although plasma viral load drops dramatically after initiation of powerful antiretrovirals,
it does not drop to zero. It appears that a new steady state is reached, suggesting that a
reservoir may exist of virus-producing cells, possibly cells of monocyte/macrophage lineage,
that continue to produce a low level of virus despite antiretroviral treatment.
Phase:
N/A
Details
Lead Sponsor:
National Institute of Allergy and Infectious Diseases (NIAID)